<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 45-year-old man presents for follow-up to monitor his chronic hepatitis C treatment. The patient was infected with hepatitis C genotype 1, one year ago. He has been managed on a combination of pegylated interferon-alpha and ribavirin, but a sustained viral response has not been achieved. Past medical history is significant for non-alcoholic fatty liver disease for the last 5 years. Which of the following, if added to the patients current treatment regimen, would most likely benefit this patient?? A: Emtricitabine, B: Entecavir, C: Simeprevir, D: Telbivudine, E: Tenofovir,  <response>: This is a patient with chronic hepatitis C genotype 1 infection who has failed initial treatment with pegylated interferon-alpha and ribavirin. The key points are:- Genotype 1 hepatitis C, failed initial treatment- Non-alcoholic fatty liver disease- Looking for an additional agent to add to current regimen that would most likely benefit the patientThe choices given are various antiviral medications. Simeprevir is a protease inhibitor used together with pegylated interferon-alpha and ribavirin for treatment of chronic hepatitis C genotype 1. It would be the most appropriate addition here as it is specifically indicated for this genotype and situation of failed prior treatment. The other options are medications used for hepatitis B entecavir, telbivudine, tenofovir, not C, or HIV emtricitabine, so they would not be appropriate.C: Simeprevir 